FAQ
Log In
Tuesday 23rd May 2017
News
 › 
 › 

Multiple Myeloma advances

6th April 2006

Thalidomide should be added to the standard combination drug therapy for multiple myeloma reports the Lancet. 

Its use led to longer event-free survival in a trial with 255 patients. Melphalan and prednisolone have been the standard treatment in Multiple Myeloma for over 40 years, adding thalidomide is the first advance in therapy since then.

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Multiple Myeloma advances
Author: Sue Knights
Article Id: 208
Date Added: 6th Apr 2006

Sources

Nursing Times
The Lancet

Recent Related Articles

Cancer Drugs Fund criticised

Brexit fears prompting EU nurses to desert the UK

Cap on new drugs

Children missing out on cancer drugs

Actions

Add to scrapbook
Show Comments
Add comment
Find all related articles

Tags

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2017